Lilly this week launched the most powerful AI factory wholly owned and operated by a pharmaceutical company to help its teams make meaningful medical advancements faster, more accurately and at...
Lilly, a pioneer in medicine, is deploying the largest, most powerful AI factory wholly owned and operated by a pharmaceutical company —the world’s first NVIDIA DGX SuperPOD with DGX B300...
Editor’s note: The name of NIM Agent Blueprints was changed to NVIDIA Blueprints in October 2024. All references to the name have been updated in this blog. The U.S. healthcare system...
Described as the largest system in the pharmaceutical industry, BioHive-2 at the Salt Lake City headquarters of Recursion debuts today at No. 35, up more than 100 spots from its...
“This year, every industry will become a technology industry,” NVIDIA founder and CEO Jensen Huang told attendees Wednesday during the annual J.P. Morgan Healthcare Conference. “You can now recognize and...
Generative AI is transforming drug research and development, enabling new discoveries faster than ever — and Amgen, one of the world’s leading biotechnology companies, is tapping the technology to power...
Genentech, a member of the Roche Group, is pioneering the use of generative AI to discover and develop new therapeutics and deliver treatments to patients more efficiently. A new collaboration...
Mitsui & Co., Ltd., one of Japan’s largest business conglomerates, is collaborating with NVIDIA on Tokyo-1 — an initiative to supercharge the nation’s pharmaceutical leaders with technology, including high-resolution molecular...
Scientists and healthcare researchers — once limited by the number of samples that could be studied in a wet lab, or the quality of microscopes to peer into cells —...
Academic medical centers worldwide are building new AI tools to battle COVID-19 — including at Mass General, where one center is adopting NVIDIA DGX A100 AI systems to accelerate its...
